Natera and BGI Genomics Announce Commercial Launch
Product Quick Detail
- Minimum Order
- 1
- Packaging
- N/A
- Delivery
- 15 Days
Specifications
About BGI Genomics
BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become one of the leading organizations in the genomics field. BGI Genomics is an independent division of
BGI Group, and has been listed on the ChiNext of Shenzhen Stock Exchange since July 14, 2017. BGI Genomics’ goal is to make state-of-the-art genomics highly accessible to the global research
community and clinical markets by integrating the industry’s broadest array of leading technologies, including DNBSEQ™ technology on the MGI sequencing platforms, economies of scale, and expert
bioinformatics resources.
- Country:
- Business Type:
- Market:
- Founded Year:
- Address:
- Contact:Tommy Ru
Other products from BGI Genomics
Relate products of Natera and BGI Genomics Announce Commercial Launch
Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform
SAN CARLOS, Calif. and SHENZHEN, China, March 11, 2019 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the largest cell-free DNA clinical testing laboratory in China and one of the ...
